Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Mazdutide in Subjects With and Without Renal Impairment
NCT05793450Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of mazdutide in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Innovent Biologics. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve. Started May 2023; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05793450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05793450.